DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Peregrine Pharmaceuticals (NASDAQ: PPHM)

1.28 -0.04 (-3.03%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PPHM $1.28 -3.03%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.30
Previous Close $1.32
Daily Range $1.28 - $1.33
52-Week Range $1.27 - $3.18
Market Cap $233.1M
P/E Ratio -4.89
Dividend (Yield) $0.00 (0.0%)
Volume 869,588
Average Daily Volume 1,050,565
Current FY EPS -$0.32

Sector

Healthcare

Industry

Drugs

Peregrine Pharmaceuticals (PPHM) Description

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases. Website: http://www.peregrineinc.com/

News & Commentary

This Potentially Game-Changing Experimental Drug Could Make or Break Peregrine Pharmaceuticals

This stock could double or be cut in half -- it really just depends on how well this revolutionary cancer drug performs in a late-stage study.

Peregrine Pharmaceuticals Series E Preferred Stock Shares Cross 12% Yield Mark

Ex-Div Reminder For Peregrine Pharmaceuticals Series E Convertible Preferred Stock

Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript

Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast

Earnings Reaction History: Peregrine Pharmaceuticals Corporation, 42.9% Follow-Through Indicator, 15

Earnings Reaction History: Peregrine Pharmaceuticals Corporation, 42.9% Follow-Through Indicator, 15.0% Sensitive

Avid Bioservices Announces Expansion Of cGMP Manufacturing Capacity

Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape

Lung Cancer Incidence Is the Highest in These 10 States

Lung cancer is estimated to have claimed 160,000 lives in the U.S. in 2013, and it's particularly common in these 10 states. Find out what's being done to improve patients' quality of life and overall survival in lieu of this terrible disease.

Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog

See More PPHM News...

PPHM's Top Competitors

PPHM $1.28 (-3.03%)
Current stock: PPHM
AMGN $152.26 (-2.63%)
Current stock: AMGN
GILD $104.83 (0.62%)
Current stock: GILD
BIIB $389.16 (10.17%)
Current stock: BIIB